Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACTH in Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome
NCT06079788Phase 3Recruiting
- Start
- Nov 2023
- Primary completion
- Jun 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of repository corticotropin injection in nephrotic syndrome (2 arms). Primary endpoint: Recurrence-free survival time at 48 weeks. Started Nov 2023; status: recruiting.
02
Drugs
repository corticotropin injection
03
Conditions
nephrotic syndrome
Beyond the preview
Go deeper on NCT06079788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079788.